Immune to Cancer: The CRI Blog
-
ASCO 2016 Update: Immunotherapy & Melanoma: The Path to Progress
Improved approaches for treating patients with melanoma.
-
FDA Approval Expands Immunotherapy Options for Advanced Melanoma
Immunotherapy combinations continue to shine against melanoma.
-
FDA Approves Immunotherapy to Help Prevent Relapse of Melanoma
The immunotherapy drug ipilimumab (Yervoy®) can now be used to help prevent relapse after surgery.
-
FDA Approves First in a New Class of Immunotherapies
Amgen’s oncolytic virus immunotherapy, T-VEC, gets the green light from the FDA.
-
In a First, FDA Approves Immunotherapy Combination for Advanced Melanoma
The approval of a combination of two immunotherapy drugs for melanoma represents a treatment milestone.
-
Jimmy Carter to Receive Immunotherapy for Melanoma
The former president will receive a drug called pembrolizumab, a PD-1-blocking antibody.
-
European Regulators Approve Pembrolizumab (Keytruda) as First-line Treatment of Advanced Melanoma
The decision makes pembrolizumab the second PD-1-blocking drug to receive approval in Europe.
-
Merck’s PD-1 Drug Outperforms Ipilimumab for Treatment of Advanced Melanoma
Data from a phase III trial indicate that Keytruda stands ready to become standard-of-care for advanced melanoma.
-
New Cancer Immunotherapy Opdivo Approved by FDA
Just hours ago, the FDA approved Bristol-Myers Squibb's PD-1 drug for melanoma.